313 related articles for article (PubMed ID: 11019371)
1. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
3. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
4. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
6. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
7. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Akaza H; Usami M; Kotake T; Koiso K; Aso Y
Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
[TBL] [Abstract][Full Text] [Related]
10. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
12. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
14. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
15. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
16. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
17. [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
Sato N; Kotake T; Masai M; Sakai S; Ito H
Hinyokika Kiyo; 2000 Jan; 46(1):1-7. PubMed ID: 10723656
[TBL] [Abstract][Full Text] [Related]
18. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
